Zimu Gong, MD
Hematology & Oncology · Oklahoma City, OKNPI 1184120560
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,701 of the $2,289 with a category attached, or 74.3%. 20 manufacturers reported payments, led by Lilly USA, LLC at 25.5% of the total. Reporting peaked in 2022 at $740 and has fallen 79.0% since, to $156 in 2025. That places this record below the midpoint for hematology & oncology clinicians in OK, where the typical reported total is $2,658.
Across 51 payments — averaging $44.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$584
- Takeda Pharmaceuticals U.S.A., Inc.$308
- Sanofi$289
- Astellas Pharma US Inc$147
- Incyte Corporation$145
- Novartis$125
- plus $690 from 14 others
Across 1 payment — averaging $26,656 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$27K
What the payments were for
- Food & beverage$1,70174%
- Education$58726%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 11 | $584 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $308 |
| Sanofi | 3 | $289 |
| Astellas Pharma US Inc | 4 | $147 |
| Incyte Corporation | 2 | $145 |
| Novartis | 6 | $125 |
| ADC Therapeutics America, Inc. | 1 | $117 |
| Bristol Myers Squibb | 2 | $110 |
| Amgen | 1 | $86 |
| Pfizer | 3 | $69 |
| Rigel Pharmaceuticals, Inc. | 1 | $61 |
| Janssen Scientific Affairs, LLC | 1 | $59 |
| Tactile Systems Technology Inc | 2 | $29 |
| Array Biopharma Inc | 1 | $27 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Sobi, Inc | 1 | $24 |
| Taiho Oncology, Inc. | 1 | $23 |
| Legend Biotech USA Inc. | 1 | $20 |
| BTG International Inc. | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,289 in reported general payments places this provider in the 45th percentile of 118 hematology & oncology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Oklahoma City
- Romeo MandanasOklahoma City$160K
- Mohammad RazaqOklahoma City$56K
- Sami IbrahimiOklahoma City$41K
- Jennifer Holter-ChakrabartyOklahoma City$39K
- Hassan HatoumOklahoma City$23K
- Abdul Rafeh NaqashOklahoma City$23K
- Taha Al-JuhaishiOklahoma City$23K
- Adanma Anji Ayanambakkam AttanathiOklahoma City$16K
- Robert ReynoldsOklahoma City$15K
- Sadia ChohanOklahoma City$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.